Kronox Lab Sciences Share Price & Earnings Call Analysis
- Market cap
- ₹734 Cr
- P/E
- 25.67
- ROE
- 26.77%
- PEG
- 1.36
- Price to sales
- 6.97
- Debt to equity
- 0.01
- 52W high / low
- ₹219 / ₹97.0
- Sales growth (5Y)
- 10.14%
- EBITDA margin
- 33.41%
- Net profit margin
- 27.27%
- Promoter holding
- 64.26%
- Sales (last year)
- ₹105 Cr
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Kronox Lab announcements
All announcements →- Acquisition / mergerNotableKronox Lab Sciences approves acquisition of plant from Axiom Chemicals Pvt Ltd
- Acquisition / mergerNotableKronox Lab Sciences Ltd: Completion of 64.26% share transfer and promoter change
- Acquisition / mergerNotableKronox Lab Sciences: promoter stake transferred to Indo Borax; board reconstituted
Financials of Kronox Lab
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Kronox Lab
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 21.47 | 25.95 | 21.02 | 20.71 | 22.18 | 25.19 | 24.86 | 24.01 | 26.13 | 24.29 | 25.53 | 25.27 | 26.13 |
| Expenses + | 17.48 | 17.43 | 15.16 | 14.63 | 14.33 | 16.98 | 16.06 | 15.65 | 18.38 | 16.32 | 16.88 | 17.24 | 16.61 |
| Operating Profit | 3.99 | 8.52 | 5.86 | 6.08 | 7.85 | 8.21 | 8.80 | 8.36 | 7.75 | 7.97 | 8.65 | 8.03 | 9.52 |
| OPM % | 18.58% | 32.83% | 27.88% | 29.36% | 35.39% | 32.59% | 35.40% | 34.82% | 29.66% | 32.81% | 33.88% | 31.78% | 36.43% |
| Other Income + | 0.14 | 0.24 | 0.49 | 0.02 | 0.83 | 0.43 | 0.36 | 0.82 | 0.91 | 0.87 | 1.04 | 1.13 | 2.15 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Depreciation | 0.30 | 0.32 | 0.38 | 0.30 | 0.29 | 0.33 | 0.34 | 0.36 | 0.35 | 0.40 | 0.47 | 0.52 | 0.66 |
| Profit before tax | 3.83 | 8.44 | 5.97 | 5.80 | 8.39 | 8.31 | 8.82 | 8.82 | 8.31 | 8.44 | 9.18 | 8.60 | 10.97 |
| Tax % | 36.55% | 24.53% | 27.14% | 18.28% | 29.92% | 25.99% | 26.64% | 26.08% | 24.07% | 25.71% | 27.23% | 23.37% | 26.98% |
| Net Profit + | 2.44 | 6.38 | 4.35 | 4.74 | 5.88 | 6.15 | 6.47 | 6.53 | 6.32 | 6.28 | 6.68 | 6.59 | 8.00 |
| EPS in Rs | 0.66 | 1.72 | 1.17 | 1.28 | 1.58 | 1.66 | 1.74 | 1.76 | 1.70 | 1.69 | 1.80 | 1.78 | 2.16 |
Financials of Kronox Lab
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 50 | 62 | 82 | 96 | 90 | 100 | 101 |
| Expenses + | 39 | 48 | 63 | 74 | 62 | 67 | 67 |
| Operating Profit | 12 | 15 | 20 | 22 | 28 | 33 | 34 |
| OPM % | 23% | 24% | 24% | 23% | 32% | 33% | 34% |
| Other Income + | 1 | 1 | 1 | 2 | 2 | 3 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 | 1 | 1 | 2 |
| Profit before tax | 12 | 13 | 18 | 22 | 29 | 34 | 37 |
| Tax % | 27% | 26% | 26% | 26% | 25% | 26% | 26% |
| Net Profit + | 9 | 10 | 14 | 16 | 21 | 25 | 28 |
| EPS in Rs | 343.60 | 403.73 | 565.56 | 4.42 | 5.75 | 6.86 | 7.45 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 7% | 7% |
Financials of Kronox Lab
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.24 | 0.24 | 37 | 37 | 37 | 37 |
| Reserves | 23 | 27 | 40 | 8 | 29 | 53 | 79 |
| Borrowings + | 0 | 4 | 3 | 0 | 0 | 0 | 2 |
| Other Liabilities + | 11 | 7 | 13 | 9 | 8 | 9 | 10 |
| Total Liabilities | 34 | 38 | 57 | 54 | 74 | 99 | 128 |
| Fixed Assets + | 6 | 9 | 11 | 16 | 26 | 28 | 29 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 29 | 28 | 45 | 38 | 47 | 70 | 98 |
| Total Assets | 34 | 38 | 57 | 54 | 74 | 99 | 128 |
Financials of Kronox Lab
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 11 | 9 | 20 | 17 | 31 | 24 |
| Cash from Investing Activity + | -4 | -3 | -8 | -7 | -17 | -28 | -24 |
| Cash from Financing Activity + | -0 | -7 | -1 | -13 | 0 | -2 | -0 |
| Net Cash Flow | 0 | 1 | 1 | -0 | 0 | 0 | -0 |
| Free Cash Flow | 3 | 10 | 5 | 11 | 5 | 28 | 21 |
| CFO/OP | 65% | 100% | 70% | 117% | 87% | 120% | 98% |
Financials of Kronox Lab
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 110 | 90 | 114 | 71 | 72 | 72 | 76 |
| Inventory Days | 70 | 58 | 58 | 61 | 74 | 46 | 66 |
| Days Payable | 102 | 69 | 89 | 52 | 51 | 52 | 52 |
| Cash Conversion Cycle | 78 | 79 | 84 | 80 | 94 | 66 | 90 |
| Working Capital Days | 100 | 95 | 122 | 83 | 143 | 168 | 71 |
| ROCE % | 50% | 51% | 50% | 52% | 44% | 36% |
Momentum score · price trend
85 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +31.1% | 79% |
| Last 6 months | +40.0% | 87% |
| Last 3 months | +26.4% | 92% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Kronox Lab: 0.4 × 79 + 0.4 × 87 + 0.2 × 92 = 85.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.